About this Research Topic
C1 inhibitor deficiencies and other hereditary angioedemas cause unpredictable swellings, which are disabling, disfiguring and may cause premature death. Those affected and their families report substantial loss of quality of life, work impairment, with increased prevalence of anxiety and depression. In recent years, better understanding of the aetiology has led to the development of several treatments to terminate acute angioedema attacks, along with effective prophylactic options for those whose angioedema is not adequately controlled by early treatment. Such rapid progress has been made possible by ongoing collaborations between scientists, medics, pharmaceutical companies and patient groups.
Our aim for patients and families living with hereditary angioedema is restoration of normal quality of life, enabling full participation in society. Thanks to recent advances in understanding of the pathogenesis of hereditary and other non-histaminergic angioedemas, coupled with availability of highly effective, patient-administered acute and prophylactic therapies, this aim is now achievable for many. However, gaps in our knowledge, inequities related to geography or lack of evidence for ultra-rare angioedemas present ongoing challenges.
In collaboration with the XIIth C1 inhibitor Deficiency and Hereditary Angioedema Workshop this Research Topic will expand on data on current knowledge, recent progress and future plans in the field of C1 inhibitor deficiency and hereditary angioedema.
This Research Topic will publish Original Research Articles, Reviews, Systematic Reviews, Mini Reviews, Methods, Policy and Practice Reviews, Hypothesis and Theory, Perspectives, Clinical Trials, Case Reports and Community Case Studies, Classifications, Data Reports, Policy Briefs, Brief Research Reports, Study Protocols, and Opinion articles covering:
- Basic research and diagnostics
- Genetics
- Clinical Aspects
- Treatment and Clinical Trials
- N = 1: learning from individuals with hereditary angioedema (case reports and series)
- Hereditary angioedema and SARS-CoV-2
- Quality of Life
- National Surveys
The meeting abstracts can now be found here: https://www.frontiersin.org/books/12TH_C1-INHIBITOR_DEFICIENCY__ANGIOEDEMA_WORKSHOP/4421#nogo
Our aim for patients and families living with hereditary angioedema is restoration of normal quality of life, enabling full participation in society. Thanks to recent advances in understanding of the pathogenesis of hereditary and other non-histaminergic angioedemas, coupled with availability of highly effective, patient-administered acute and prophylactic therapies, this aim is now achievable for many. However, gaps in our knowledge, inequities related to geography or lack of evidence for ultra-rare angioedemas present ongoing challenges.
In collaboration with the XIIth C1 inhibitor Deficiency and Hereditary Angioedema Workshop this Research Topic will expand on data on current knowledge, recent progress and future plans in the field of C1 inhibitor deficiency and hereditary angioedema.
This Research Topic will publish Original Research Articles, Reviews, Systematic Reviews, Mini Reviews, Methods, Policy and Practice Reviews, Hypothesis and Theory, Perspectives, Clinical Trials, Case Reports and Community Case Studies, Classifications, Data Reports, Policy Briefs, Brief Research Reports, Study Protocols, and Opinion articles covering:
- Basic research and diagnostics
- Genetics
- Clinical Aspects
- Treatment and Clinical Trials
- N = 1: learning from individuals with hereditary angioedema (case reports and series)
- Hereditary angioedema and SARS-CoV-2
- Quality of Life
- National Surveys
The meeting abstracts can now be found here: https://www.frontiersin.org/books/12TH_C1-INHIBITOR_DEFICIENCY__ANGIOEDEMA_WORKSHOP/4421#nogo
Keywords: C1 inhibitor, angioedema, bradykinin, kallikrein, factor XII, complement, deficiency
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
